2,2,2-trifluoro-N-(4-fluorobenzyl)ethanamine hydrochloride | 405879-03-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,2,2-trifluoro-N-(4-fluorobenzyl)ethanamine hydrochloride
• 英文别名: p-Fluorobenzyl-2,2,2-trifluoroethyl-amine hydrochloride；[(4-Fluorophenyl)methyl](2,2,2-trifluoroethyl)amine hydrochloride；2,2,2-trifluoro-N-[(4-fluorophenyl)methyl]ethanamine;hydrochloride
• CAS: 405879-03-0
• 化学式: C₉H₉F₄N*ClH
• mdl: MFCD20441720
• 分子量: 243.632
• InChiKey: NPOTUBGUHSNDBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.63
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,2,2-trifluoro-N-(4-fluorobenzyl)acetamide 在 tropylium tetrafluoroborate 、 频那醇硼烷 、 sodium hydroxide 、 盐酸 作用下， 以 乙醚 为溶剂， 反应 3.0h， 以68%的产率得到2,2,2-trifluoro-N-(4-fluorobenzyl)ethanamine hydrochloride
  参考文献：
  名称：

  Tropyium 四氟硼酸盐促进腈、亚胺和酰胺的硼氢化

  摘要：

  腈类（现成的合成前体）转化为胺、亚胺或酰胺是合成实验室和工业化学中重要的化学转化。有各种各样的方法来促进这种类型的化学。但是，仍然存在一些限制。为了追求实用且环境友好的腈硼氢化反应，我们开发了一种新的有机催化方法，用频哪醇硼烷将腈、亚胺或酰胺还原为胺。通过将进一步的官能化反应引入到一锅中的粗硼氢化混合物中，可以方便地获得来自这些胺的有价值的衍生物。

  DOI：

  10.1039/d2gc01905a

文献信息

• Imidazolyl derivatives as corticotropin releasing factor inhibitors
  申请人：——

  公开号：US20020183375A1

  公开（公告）日：2002-12-05

  The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1 useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及一种新型杂环拮抗剂，其化学式为(I)，以及包含所述拮抗剂的药物组合物，用于治疗抑郁症、焦虑症、情感障碍、进食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状以及其他可以通过拮抗CRF-1受体来治疗的病症。
• Substituted azole derivatives as inhibitors of corticotropin releasing factor
  申请人：——

  公开号：US20020161019A1

  公开（公告）日：2002-10-31

  The present invention relates to thiazoles, oxazoles, imidazoles and pharmaceutical compositions comprising said compounds antagonizing the corticotropin releasing factor receptor (“CRF receptor”) and useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及噻唑、噁唑、咪唑及含有这些化合物的药物组合物，其拮抗促肾上腺皮质激素释放因子受体（“CRF受体”），并可用于治疗抑郁症、焦虑症、情感障碍、饮食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状和其他可以通过拮抗CRF-1受体来治疗的疾病。
• [EN] SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR<br/>[FR] DERIVES D'AZOLE SUBSTITUES EN TANT QU'INHIBITEURS DU FACTEUR DE LIBERATION DE LA CORTICOTROPINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002024200A1

  公开（公告）日：2002-03-28

  The present invention relates to thiazoles, oxazoles, imidazoles and pharmaceutical compositions comprising said compounds antagonizing the corticotropin releasing factor receptor ('CRF receptor') and useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be affected by the antagonism of the CRF-1 receptor.

  本发明涉及噻唑、噁唑、咪唑及包含该类化合物的药物组合物，其对促肾上腺皮质激素释放因子受体（“CRF受体”）具有拮抗作用，并且可用于治疗抑郁症、焦虑症、情感障碍、进食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状以及其他可能受CRF-1受体拮抗作用影响的疾病的治疗。
• [EN] IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS<br/>[FR] DERIVES IMIDAZOLYLES COMME INHIBITEURS DU FACTEUR DE LIBERATION DE LA CORTICOTROPINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002058704A1

  公开（公告）日：2002-08-01

  The present invention relates to novel heterocyclic antagonists of Formula I and pharmaceutical compositions comprising said antagonists of the coticotropin releasing factor receptor ('CRF receptor') (formula), useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及公式I的新型杂环拮抗剂和包含所述拮抗剂的药物组合物，该药物组合物对促肾上腺皮质激素释放因子受体（'CRF受体'）具有拮抗作用，用于治疗抑郁症、焦虑症、情感障碍、饮食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状和其他可以通过CRF-1受体的拮抗作用治疗的疾病。
• An efficient sequence for the preparation of small secondary amine hydrochloride salts for focused library generation without need for distillation or chromatographic purification
  作者：Gene M. Dubowchik、Jodi A. Michne、Dmitry Zuev

  DOI：10.1016/j.bmcl.2004.04.014

  日期：2004.6

  Collections of small secondary amines for compound library generation can be efficiently prepared by amide reduction using BH(3)-THF or Red-Al followed by brief methanolysis, trapping with di-tert-butyl dicarbonate, and deprotection with 4M HCl in dioxane. The sequence requires no chromatography or distillation and provides multi-gram quantities of pure HCl salts in a short time.